Research paper

Early postnatal hypoferremia in low birthweight and preterm babies: A prospective cohort study in hospital-delivered Gambian neonates

James H. Cross\textsuperscript{a}, Ousman Jarjour\textsuperscript{a}, Nuredin Ibrahim Mohammed\textsuperscript{a}, Santiago Rayment Gomez\textsuperscript{b}, Bubacarr J.B Touraya\textsuperscript{a}, Andrew M. Prentice\textsuperscript{c}, Carla Cerami\textsuperscript{a}\textsuperscript{*}

\textsuperscript{a} Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Atlantic Boulevard, Fajara, P.O. Box 273, Banjul, The Gambia
\textsuperscript{b} Cardiff University, Cardiff, Wales, CF10 3AT, United Kingdom

Abstract

Background: Neonates, particularly those born preterm (PTB) and with low birthweight (LBW), are especially susceptible to bacterial and fungal infections that cause an estimated 225,000 deaths annually. Iron is a vital nutrient for the most common organisms causing sepsis. Full-term babies elicit an immediate postnatal hypoferremia assumed to have evolved as an innate defence. We tested whether PTB and LBW babies are capable of the same response.

Methods: We conducted an observational study of 152 babies who were either PTB (born \(\geq 32\) to \(<37\) weeks gestational age) and/or LBW (\(<2500\) g) (PTB/LBW) and 278 term, normal-weight babies (FTB/NBW). Blood was sampled from the umbilical cord vein and artery, and matched venous blood samples were taken from all neonates between 6–24 h after delivery. We measured haematological, iron and inflammatory markers.

Findings: In both PTB/LBW and FTB/NBW babies, serum iron decreased 3-fold within 12 h of delivery compared to umbilical blood (7.5 \(\pm\) 4.5 vs 23.3 \(\pm\) 7.1 ng/ml, \(P < 0.001, n = 425\)). Transferrin saturation showed a similar decline with a consequent increase in unsaturated iron-binding capacity. C-reactive protein levels increased over 10-fold (\(P < 0.001\)) and hepcidin levels doubled (\(P < 0.001\)). There was no difference in any of these responses between PTB/LBW and FTB/NBW babies.

Interpretation: Premature or low birthweight babies are able to mount a very rapid hypoferremia that is indistinguishable from that in normal term babies. The data suggest that this is a hepcidin-mediated response triggered by acute inflammation at birth, and likely to have evolved as an innate immune response against bacterial and fungal septicaemia.

Trial registration: clinicaltrials.gov (NCT03353051). Registration date: November 27, 2017.

Funding: Bill & Melinda Gates Foundation (OPP1152353).

\* Corresponding author.

E-mail address: cerami@mrc.gm (C. Cerami).

1. Introduction

Neonatal sepsis is the third highest cause of death globally, accounting for 225,000 deaths each year [1]. It is projected that these numbers will increase as a consequence of the increasing global prevalence of antimicrobial resistance [2].

Physiological adaption to the postnatal environment in the first hours of life is critical for survival. At birth, babies transition from a semi-allogeneic, protected fetal setting to a microbe-rich extrauterine environment [3]. The initial mass bacterial colonisation of mucosa in the digestive, respiratory and urogenital tracts, as well as the skin, occurs during the very early neonatal period [4]. The maternal gut is the source of the majority of transmitted bacterial strains to the neonatal microbiome and common strains are also seeded from the maternal skin and the vaginal microbiome [5]. The acquisition of symbionts can positively affect gut maturation, metabolic homeostasis and immune function in early life and beyond [6], but pathogenic bacteria and fungi pose an immediate risk unless contained. Adaptive immune responses require priming in neonates, and hence innate defence mechanisms play an important role in containment.

Similarly, just before delivery or during the intrapartum period, babies can be infected by micro-organisms, which may lead to early-
onset neonatal sepsis (EONS) especially if the mother is colonised with pathogenic bacteria [7]. Aspiration or ingestion of infected amniotic fluid in utero or infected secretions at birth are the common routes of infection.

Iron is an important commodity in the host-pathogen battle for resources [8]. It is a cofactor in numerous metabolic pathways that are critical for the human host as well as most pathogens. Therefore, systemic iron distribution is strictly regulated by the host [9]. For many human pathogens, the acquisition of iron via a variety of molecular mechanisms can enhance growth and virulence [8]. Individuals with chronically high iron states (e.g. haemochromatosis) have an enhanced risk of bacterial infection [10], as well as increased free radical redox damage [11]. Historic studies administering parenteral iron to Polynesian neonates infamously increased mortality rates by promoting Escherichia coli septicemias [12], underlining the critical role of iron in the neonatal period.

Cord blood, which has high levels of serum iron and transferrin saturation [13], has frequently been used as a proxy for neonatal iron status. However, previous work by our group and others has shown that healthy, vaginally-delivered, full-term babies profoundly decrease their serum iron and TSAT levels in the first 24 h after birth; an adaptation that may have evolved as an innate defence against iron-requiring microorganisms [14]. In the current study, we hypothesised that the greater susceptibility of preterm and low birthweight babies to neonatal infections might be because they are less able to elicit this defence. We prospectively tested this in hospital-delivered Gambian neonates.

2. Participants and methods

Full details of the methods of this study can be found in the published protocol paper [15].

2.1. Study design

This observational study recruited well, hospital-delivered neonates into four different groups characterised according to birthweight and gestational age as shown in Fig. 1. The primary analysis compares all babies exhibiting preterm birth (PTB), low birthweight (LBW) or both (PTB/LBW) versus full-term (FTB), normal birthweight (NBW) (FTB/NBW) newborns. Secondary analyses examine the PTB +NBW, FTB+LBW and PTB+LBW groups separately.

2.2. Ethics, standards and informed consent

The study was approved by the Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine (MRCG at LSHTM) Scientific Coordinating Committee, the Joint Gambia Government/MRCG Ethics Committee (SCC1525) and the London School of Hygiene and Tropical Medicine Ethics Committee (Ref: 14316). The study was conducted according to Good Clinical Practice (GCP) standards. All participants gave written, informed consent.

2.3. Study setting

Study participants were recruited from Kanifing General Hospital (formerly Serrekunda General Hospital), in the urban Kanifing region of The Gambia, West Africa.

2.4. Recruitment, screening and enrolment

In total, we planned to identify 450 healthy newly born babies during delivery at the Kanifing General Hospital Maternity Ward. After informed consent was obtained, neonates who met the inclusion criteria were enrolled. For inclusion in the study, neonates were medically stable (no birth asphyxia nor signs of sepsis as judged by the study physician), ≥32 weeks gestational age and weighed ≥2000 g. Preterm babies (PTB) were <37 completed weeks gestational age (assessed by New Ballard Score [16]). Term babies (FTB) had a gestational age ≥37 completed weeks. Low birthweight (LBW) was defined as <2500 g in line with the usual WHO definition. Neonates, who weighed ≥2500 g were defined as normal birthweight (NBW). The observational period began at delivery and lasted until the end of the 7th day of life. Data collection started on the 5th July 2017 and ended on 1st February 2019.

Pregnant mothers were excluded from the study if they were below the age of 18 years, had no fetal heartbeat detected upon admission, were known to be HIV-positive, were in receipt of Mycobacterium tuberculosis therapy, had taken antibiotics in the last seven days, had a blood transfusion in the last month, were suffering from severe pre-eclampsia or antepartum haemorrhage, or were in another research study.

Babies were excluded at the delivery stage for the following reasons: major congenital malformations (not including polydactylism),
blood transfusions given to mother or neonate, severe birth asphyxia (requiring resuscitation), neonates born via breech, vacuum or via caesarean section, or a birthweight < 2000 g (in order to avoid the additional burden of a blood draw in these vulnerable neonates as guided by the Gambia Government/MRCG and LSHTM Ethics Committees).

After the delivery stage, babies were excluded following the detection of infection or illness (information gained from a venous bleed or review of systems). Neonates were also removed from the study protocol, if any medication other than intramuscular vitamin K, tetracycline eye ointment or immunisations were given. All medications given to mothers and neonates during the study period were recorded. Mothers who delivered multiple newborns were invited to enrol one of their neonates into the study.

2.5. Sample collection

Once the neonate was fully delivered, one-minute delayed cord clamping was used (following World Health Organisation (WHO) policy [17]). After the umbilical cord was removed and cleaned, a trained study nurse identified the umbilical arteries and umbilical vein. Blood was collected from each using separate blood draw equipment.

At 6–24 h post-delivery, recruited mothers and their neonates were invited to a private consultation with the study research clinician. Further demographic data were collected, along with a complete review of systems of the mother and neonate. Anthropometric data on the newborn was also collected at this point. Neuromuscular and physical maturation of each neonate was assessed using the New Ballard Score [16]. Immediately after passing the health assessment, a venous blood draw was performed on all neonates (2 ml for PTB/LBW neonates and 3-5 ml for FTB/NBW neonates).

2.6. Laboratory analyses

A full haematology panel (using a Medonic M20M GP, Boule Diagnostics, Spanga, Sweden) and glucose-6-phosphate dehydrogenase deficiency test (R&D Diagnostics Limited, Papagos, Greece) were conducted on whole blood. Serum was separated and stored at −20 °C prior to analysis of ferritin, iron, unsaturated iron-binding capacity (UIBC), soluble transferrin receptor (sTfR), transferrin, C-reactive protein (CRP), haptoglobin and alpha-1-acid glycoprotein (AGP) using a fully automated biochemistry analyser (Cobas Integra 400 plus, Roche Diagnostic, Switzerland). Transferrin saturation (TSAT) was calculated. Serum samples were assessed for hepcidin concentration by ELISA (hepcidin-25 (human) EIA Kit, DRG, USA) with a dynamic range of 0–135–81 ng/ml.

In order to ensure a consistent assessment of haemolysis in all serum samples, batches of samples were thawed before entering the biochemistry analyser and visually scored by a single operator. A previously published specimen integrity chart for haemolysis was used as reference [18]. Samples were scored 0 (yellow 0 g/L) to 6 (dark red 8 g/L). Samples scoring ≥5 were removed from the analysis.

2.7. Sample size determination

This study targeted recruitment of 50 neonates in each of the 3 groups PTB, LBW and PTB+LBW and 300 FTB/NBW newborns. Sample size calculations for the primary outcomes of change in serum iron and TSAT between cord and the first neonatal samples were based on data from a previous study [14] and are summarised in the published protocol paper [15]. All secondary analyses are considered exploratory and were not subjected to a formal sample size calculation.

2.8. Statistical analysis

The primary analysis compared responses in the PTB and/or LBW babies combined (PTB/LBW) versus FTB/NBW. Further subgroups of the PTB/LBW group (groups A-C as summarised in Fig. 1) were also examined in the secondary analyses (see Supplementary Material). For continuous variables, baseline characteristics are presented as means (± SD) for normally distributed variables. All skewed data were transformed using the ladder command in STATA. The ladder command searches a subset of the ladder of powers for a transformation that converts the variable of
interest into a normally distributed variable. Results were confirmed graphically by the gladder command. Categorical variables are reported as proportions. The rate of missing data was small (<5%), thus we did not impute missing data. Participant characteristics and iron status indicators were compared using 2-tailed t-tests or $\chi^2$ tests. Multiple regression was used to explore relationships between iron status indicators, participant characteristics, inflammatory and haematology markers. The relative strength of associations was assessed using standardised coefficients, which represent the effect on the outcome variable (expressed as a fraction of a standard deviation) caused by a one standard deviation change in the predictor variable. Changes between cord and postnatal blood samples were assessed by paired t-tests. Comparisons of continuous variables between groups A-D were produced using repeat measures one-way analysis of variance. We examined the association between covariates and the three outcomes iron, TSAT and hepcidin status using linear regression models with backward elimination for variable selection. All models were adjusted for baseline (cord blood) levels. Unless otherwise stated, all hypothesis tests were two-sided at significance level of 0.05. All analyses were performed using DataDesk (Data Description Inc, Ithaca, USA) and STATA 15 (StataCorp LLC, Texas, USA).

3. Results

Fig. 2 is the CONSORT diagram summarising subject recruitment. Baseline characteristics for the 430 neonates completing the study are shown in Table 1. As per protocol, there was a large difference in birthweight between NBW (3199 ± 376 g) and LBW (2338 ± 118 g) newborns, with associated differences in length and head circumference. Gestational age was also lower in the PTB babies (35.6 ± 0.7) than FTB (39.4 ± 1.3 wk). When the LBW and PTB babies were combined as PTB/LBW, their weight and gestational ages were significantly lower than the FTB/NBW newborns. Mothers of low birthweight babies were younger (39.8 ± 3.5 yr) than FTB mothers (41.4 ± 3.7 yr), and had a higher TSAT (54.2 ± 5.7 mol/L) than FTB neonates. There is no evidence that these small differences in TSAT will translate into a hypoferremic response and very few in whom the response was only moderate. Fig. 4 shows that the decline had already occurred by the beginning of our sampling window at 6 h post-delivery. Contrary to our initial hypothesis, there was no difference in the hypoferremic response between any of the PTB, LBW or PTB/LBW groups and the controls. For all the babies combined, serum iron decreased over 3-fold from 23.3 ± 7.1 to 7.5 ± 4.5 μmol/L (P < 0.001) and TSAT decreased from 51.7 ± 17.3 to 15.0 ± 6.9% (P < 0.001) (Table 2). The mean decrease in serum iron from cord to postnatal blood was remarkably consistent across all groups (between 15.2 and 16.5 μmol/L), equivalent to a range from 2.9 to 3.1-fold decrease (Table 3). Likewise, the spread of the decreases in TSAT between groups was very tight (between 35 and 39%), equivalent a 3.3 to 3.5-fold reduction. Correspondingly there was a substantial increase in UIBC in all groups indicating an enhanced ability to sequester any free iron (22.9 ± 10.5 to 43.5 ± 15.9 μmol/L, P < 0.0001 for all babies combined). Notably, ferritin, TIBC and haemoglobin levels increased from cord to the first neonatal bleed, and there was no change in transferrin; thus confirming that the decrease in serum iron was an active adaptation not related to altered haemodynamics. Fig. 5 shows that all groups had similar hepcidin levels (20.9 ± 13.8 in PTB/LBW vs 19.4 ± 14.4 ng/ml in FTB/NBW) in their cord blood. However, the cord blood from PTB neonates had slightly higher TSAT values (54.8 ± 17.7 vs 50.2 ± 16.8%, P = 0.017) and serum iron (24.4 ± 7.3 vs 22.7 ± 7.0 μmol/L, P = 0.017) in comparison to FTB neonates. In the postnatal venous blood samples all groups had similar hepcidin levels (37.4 ± 23.5 in PTB/LBW vs 38.9 ± 23.9 ng/ml in FTB/NBW). The venous blood from PTB and LBW neonates had slightly higher TSAT values (16.1 ± 4.8% and 16.2 ± 5.3% vs 14.4 ± 6.0%) in comparison to FTB neonates. There is no evidence, that these small differences in TSAT will translate into a
clinically important difference in susceptibility to neonatal sepsis or infection. Additional comparisons can be seen in Supplementary Tables 3 & 4. Comparisons of further iron, infection and haematological parameters in umbilical cord and venous blood can be seen in Supplementary Table 5. Analysis of the babies subdivided into groups A-D is listed in Supplementary Tables 6, 7 and 8. As anticipated, based upon the lack of difference in hypoferremia between PTB, LBW and FTB/LBW neonates, there were no differences between the additional subgroupings of A-D.

3.2. Factors associated with the decline in serum iron and TSAT

CRP levels increased by over 10-fold between cord and postnatal blood (0.17 ± 0.6 to 2.16 ± 4.0 mg/L, P < 0.001) and hepcidin levels doubled (19.9 ± 14.2 to 38.4 ± 23.7 ng/ml, P < 0.001). Fig. 4 illustrates the timecourse of the changes.

Table 3 lists the results of regression analysis of factors associated with Day 1 serum iron. Use of standardised coefficients permits ranking in order of the effect size per standard deviation of the predictor variable. In univariate analysis CRP, hepcidin and transferrin were most strongly associated with serum iron. Note that CRP was entered as the reciprocal of the square root, so the direction of the coefficient is reversed (i.e. a high CRP was associated with a low serum iron). Haptoglobin, age of mother and birthweight were also significantly associated with serum iron. In multivariable analysis, CRP and hepcidin were the strongest correlates. The parallel analysis for TSAT showed broadly similar associations (Table 3).

3.3. Factors associated with postnatal hepcidin levels

Based on the pre-hoc assumption that hepcidin orchestrates the postnatal hypoferremia, we examined the factors associated with neonatal hepcidin levels on Day 1 (Table 4). The strongest predictor was time of bleed with a negative coefficient. Examination of Fig. 4C suggests that this was because hepcidin rose very fast at, or immediately after, parturition and was already starting to decline by 6 h. Ferritin was positively associated with hepcidin, and serum iron was negatively correlated. Surprisingly there was no evidence of a cross-sectional association between hepcidin and CRP.

4. Discussion

The rapid and profound postnatal hypoferremia demonstrated in this study closely matches our prior findings in full-term, vaginally-delivered rural Gambian babies [14] and the results of studies elsewhere [19,20]. The 3.4-fold decrease recorded here is towards the top end of the 2–4 -fold range recorded in prior studies [14,19,20]. We have previously proposed that this may represent an evolved innate immune response designed to deprive blood-stream bacteria of iron and hence create a hostile bacteriostatic environment [14]. The current study was designed to test the hypothesis that immature or growth-restricted neonates might have a lesser ability to trigger this innate defence and that this might explain their greater susceptibility to septicemias [21]. Our hypothesis was firmly refuted. We showed that the premature and low birthweight neonates all exhibited a profound hypoferremia during the first 24 h of life, with no detectable differences from the full-term, normal birthweight newborns. In fact, there was a remarkable similarity in the hypoferremic response across all the study groups that underscores the efficiency of the process and supports the likelihood that it occurs by design.

The host-pathogen battle for iron has been extensively studied [22] and it has long been assumed that the hypoferremia of the acute phase response acts as an innate defence against iron-requiring organisms. Hepcidin is a key, though not necessarily the only [23], regulator of this response [24]. Inflammatory cytokines including IL-6, IL-22 and Type-1 interferon rapidly upregulate hepcidin expression and release from the liver [25]. Hepcidin causes hypoferremia by inhibiting the action of the transmembrane iron-exporter ferroportin in enterocytes and macrophages, thus blocking iron absorption and recycling [26]. Injection of recombinant hepcidin results in the very rapid induction of hypoferremia in mice [27] and humans [28].

In both univariate and multivariate analysis neonatal serum iron and TSAT levels were most strongly correlated with CRP and hepcidin (Table 3) suggesting that the hypoferremia is, at least partly, driven by an inflammatory response to the stress of the birth process and/or
Fig. 3. Analysis of serum iron (A), TSAT (B) and hepcidin (C) in umbilical cord (BLUE) and postnatal venous blood (RED) based on all study groupings. Horizontal lines represent the arithmetic group means. FTB/NBW are FTB + NBW. PTB/LBW are FTB + LBW, PTB + NBW and PTB + LBW neonates. All group comparisons between cord and venous blood are statistically significant (P < 0.001). Hepcidin displayed as log10.
the exposure of the newborn to vaginal and/or gastrointestinal microorganisms not previously encountered in utero. The modest proportion of variance explained in the full multivariate model (29% for serum iron and 22% for TSAT) might reflect the fact that both measures have been suppressed to close to their physiological lower limit and hence display a limited range. It is also possible that hepcidin-independent mechanisms, driven by effector molecules unmeasured in this study, are playing an additional role [23]. A full examination of the mechanism responsible for the hypoferremia would probably require studies in an animal model (e.g. neonatal piglets).

Using ex vivo assays with sentinel bacteria, we have previously demonstrated that low TSAT values in serum from adults [29] and neonates [14] exerts a powerful bacteriostatic effect. In the neonatal study, growth rates of *Escherichia coli*, *Streptococcus pneumoniae*, *Streptococcus agalactiae* and *Staphylococcus aureus*, were highly significantly lower in neonatal serum than in cord serum and for each organism growth rates were significantly associated with TSAT. *S. aureus* was least responsive, possibly reflecting its ability to utilise haem iron, though it was still clearly influenced by transferrin saturation. *E. coli* was most responsive, which may explain why intramuscular iron administration to Polynesian neonates increased septicaemia rates with a major shift towards *E. coli* as the most frequently identified cause [12]. The hypoferremia observed in the current hospital-based study (in both PTB/LBW and FTB/NBW babies) was more profound than we previously observed in rural home deliveries [14] (TSAT declined to 15% versus 24% in rural babies) and hence the bacteriostatic effect would be expected to be even greater.

There are several strengths and limitations to our study. The large sample size allows us to confidently exclude any clinically-meaningful differences in the postnatal response of preterm and low birthweight babies compared to the full-term normal birthweight neonates. By protocol, we did not recruit mothers with complex medical histories (e.g. pre-eclampsia, antepartum haemorrhage or antenatal infection) or sick babies (e.g. with birth asphyxia or suspected sepsis). We did not recruit newborns born <32 completed weeks gestation and/or <2000 g birthweight, or those delivered via c-section, vacuum or forceps. We cannot speculate whether similar hypoferremic responses would occur in such cases, but reciprocally we can conclude that the responses we observed are a characteristic feature of normal human birth and were not elicited by pathological circumstances. In order to allow mothers to recover from their delivery and the neonates to be stabilised and checked for inclusion, we constrained our first postnatal blood draw to after 6 h post-delivery. With many samples collected soon after this point, we have demonstrated that the reduction in circulating iron levels occurs very rapidly but we cannot state how rapidly. We did not measure pro-
| Sample Type | Whole Population | FTR/NBW | PTB/LBW | Preterm Birth (PTB) | Low Birthweight (LBW) |
|-------------|-----------------|---------|---------|---------------------|-----------------------|
|             | n   | Cord | n   | Venous | P value | n   | Cord | n   | Venous | P value | n   | Cord | n   | Venous | P value | n   | Cord | n   | Venous | P value |
| Serum Iron  | 425 | 23.3 | 421 | 7.5   | -0.001 | 275 | 22.7 | 271 | 7.3   | -0.001 | 150 | 24.3 | 150 | 8.0   | -0.001 | 140 | 24.4 | 139 | 7.8   | -0.001 |
| (μmol/L)    |     | ±7.1 |     | ±4.5  |         |     | ±7.0 |     | ±4.6  |         |     | ±7.3 |     | ±4.1  |         |     | ±7.3 |     | ±4.1  |         |
| UIC         | 423 | 22.9 | 420 | 43.5  | -0.001 | 273 | 23.7 | 271 | 44.1  | -0.001 | 150 | 21.5 | 149 | 42.2  | -0.001 | 140 | 21.2 | 138 | 42.0  | -0.001 |
| (μmol/L)    |     | ±10.5 |     | ±15.9 |         |     | ±10.4 |     | ±18.0 |         |     | ±10.6 |     | ±10.9 |         |     | ±10.8 |     | ±10.9 |         |
| TIBC        | 423 | 46.1 | 420 | 51.0  | -0.001 | 273 | 46.3 | 271 | 51.4  | -0.001 | 150 | 45.8 | 149 | 50.2  | -0.001 | 140 | 45.6 | 138 | 49.8  | -0.001 |
| (μmol/L)    |     | ±8.0  |     | ±17.9 |         |     | ±8.1  |     | ±20.7 |         |     | ±7.8  |     | ±11.3 |         |     | ±7.4  |     | ±11.1 |         |
| Transferrin | 426 | 1.96 | 423 | 1.99  | 0.003  | 275 | 1.98 | 273 | 1.98  | 0.8335 | 151 | 1.93 | 150 | 2.00  | 0.003  | 141 | 1.92 | 139 | 1.99  | 0.003  |
| (μg/L)      |     | ±0.3  |     | ±0.3  |         |     | ±0.3  |     | ±0.3  |         |     | ±0.3  |     | ±0.3  |         |     | ±0.3  |     | ±0.3  |         |
| TSAT (%)    | 423 | 51.7 | 420 | 15.0  | 0.001  | 273 | 50.2 | 271 | 14.4  | 0.001  | 150 | 54.5 | 149 | 16.2  | 0.001  | 140 | 54.8 | 138 | 16.1  | 0.001  |
|             |     | ±17.3 |     | ±8.9  |         |     | ±16.7 |     | ±6.1  |         |     | ±18.0 |     | ±8.2  |         |     | ±17.7 |     | ±8.4  |         |
| Serum ferritin | 426 | 2.015 | 415 | 381.2 | -0.001 | 275 | 2.26 | 271 | 395.9 | -0.001 | 151 | 206.6 | 149 | 356.6 | -0.001 | 141 | 206.8 | 138 | 357.7 | -0.001 |
| (μg/L)      |     | ±157.8 |     | ±267.6 |         |     | ±157.7 |     | ±312.6 |         |     | ±158.5 |     | ±268.1 |         |     | ±154.8 |     | ±259.6 |         |
| Serum MGP   | 420 | 0.18 | 423 | 0.24  | 0.001  | 275 | 0.19 | 273 | 0.25  | 0.001  | 151 | 0.17 | 150 | 0.23  | 0.001  | 141 | 0.16 | 139 | 0.22  | 0.001  |
| (μg/L)      |     | ±0.1  |     | ±0.2  |         |     | ±0.1  |     | ±0.2  |         |     | ±0.1  |     | ±0.2  |         |     | ±0.1  |     | ±0.2  |         |
| Serum CRP   | 420 | 0.17 | 422 | 2.16  | 0.001  | 275 | 0.19 | 273 | 2.27  | 0.001  | 150 | 0.14 | 149 | 1.96  | 0.001  | 140 | 0.14 | 138 | 1.99  | 0.001  |
| (mg/L)      |     | ±0.6  |     | ±4.0  |         |     | ±0.7  |     | ±4.1  |         |     | ±0.2  |     | ±3.8  |         |     | ±0.2  |     | ±3.9  |         |
| >5mg/L      | 3   | 0.78 | 83  | 19.7  | 0.001  | 3   | 1.05 | 59  | 21.6  | 0.001  | 0    | 0.05 | 24  | 16.1  | 0.001  | 0    | 0.05 | 23  | 16.7  | 0.001  |
|             |     | ±0.7  |     | ±4.0  |         |     | ±1.8  |     | ±2.6  |         |     | ±3.8  |     | ±3.9  |         |     | ±3.8  |     | ±3.9  |         |
| Serum hepcidin | 425 | 19.9 | 417 | 38.4  | -0.001 | 277 | 19.4 | 270 | 38.9  | -0.001 | 148 | 20.9 | 147 | 37.4  | -0.001 | 138 | 21.5 | 136 | 37.7  | -0.001 |
| (ng/mL)     |     | ±142  |     | ±23.7 |         |     | ±144  |     | ±23.9 |         |     | ±138  |     | ±23.5 |         |     | ±133  |     | ±23.3 |         |
| Haemoglobin | 414 | 15.3 | 423 | 19.4  | -0.001 | 270 | 15.1 | 272 | 19.1  | -0.001 | 144 | 15.6 | 151 | 19.9  | -0.001 | 136 | 15.6 | 140 | 19.8  | -0.001 |
| (g/dL)      |     | ±2.5  |     | ±3.3  |         |     | ±2.9  |     | ±3.1  |         |     | ±2.7  |     | ±3.1  |         |     | ±2.7  |     | ±3.1  |         |

Data are presented as mean (±SD) and analysed by one-way analysis of variance. P values in bold font are considered significant based on P < 0.05. Skewed variables were transformed as follows: log10(seraum iron), 1/sqrt(TIBC), sqrt(ferritin), 1/sqrt(CRP), log10(hepcidin).
inflammatory cytokines (e.g. IL-6 and IL-22) which might have provided additional insights into the mechanisms eliciting hypoferremia. Similarly, we did not attempt to address any possible hepcidin-independent mechanisms because the putative mediators remain unknown. Such studies may require animal models.

In conclusion, our results suggest that the innate postnatal iron restriction strategy in the first hours of life has evolved as an intrinsic mechanism to protect neonates from common pathogens and/or free-radical damage, and occurs regardless of gestational age or birthweight. This hypoferremia is at least partly mediated by the hormone, hepcidin. The trigger mechanism, relation to maternal iron status, and its effect on susceptibility to systemic bacterial infections require further investigation.

Our results highlight the importance of hypoferremia as a conserved mechanism of protection, and prompt further research into the use of iron restriction as a transient bacteriostatic mechanism to limit bacterial growth and virulence in other instances of infection. Hypoferremia can slow the multiplication of bacterial pathogens [29], which in combination with antibiotics, could allow enough time for the adaptive immune system to fight the infection. Augmentation of innate immunity in neonates and other at-risk groups (elderly or immunocompromised) might be achieved by small molecule orally-administered mini-hepcidins currently under development as hepcidin agonists [28,30].

Declaration of Competing Interest

The authors declare that they have no competing interests.

Acknowledgements

We thank Kanifing Municipal Council (KMC) and Kanifing General Hospital (KGH) for their support during the study.

| Table 3 | Linear regression of factors associated with postnatal serum iron and TSAT. |
| --- | --- |
| Predictor | Coefficient | Standard error | Standardised coefficient | P value | R² (%) |
| **Univariate Analysis - Serum Iron** |  |  |  |  |  |
| CRPa | 0.135 | 0.023 | 0.258 | <0.0001 | 15.5 |
| Hepcidinb | −0.129 | 0.025 | −0.249 | <0.0001 | 14.2 |
| Transferrin | 0.273 | 0.056 | 0.222 | <0.0001 | 13.7 |
| Haptoglobin | −1.21 | 0.303 | −0.184 | <0.0001 | 12.2 |
| Age of mother | −0.009 | 0.002 | −0.152 | 0.001 | 11.1 |
| Birthweight | 0.0001 | −0.0004 | −0.149 | 0.001 | 11 |
| **Multivariate Analysis - Serum Iron** |  |  |  |  |  |
| CRPa | 0.124 | 0.022 | 0.239 | <0.0001 | 29.2 |
| Hepcidinb | −0.11 | 0.025 | −0.198 | <0.0001 | 29.2 |
| Transferrin | 0.23 | 0.055 | 0.186 | <0.0001 | 29.2 |
| Haptoglobin | −0.008 | 0.002 | −0.143 | 0.001 | 29.2 |
| Birthweight | −0.0009 | 0.0003 | −0.104 | 0.001 | 29.2 |
| **Univariate Analysis - Transferrin Saturation (TSAT)** |  |  |  |  |  |
| CRPa | 0.153 | 0.023 | 0.306 | <0.0001 | 11.7 |
| Haptoglobin | −1.14 | 0.302 | −0.181 | <0.0001 | 5.7 |
| Hepcidinb | −0.085 | 0.025 | −0.16 | 0.001 | 4.8 |
| Birthweight | −0.0001 | 0.0004 | −0.153 | 0.001 | 4.7 |
| Age of mother | −0.008 | 0.002 | −0.151 | 0.002 | 4.7 |
| **Multivariate Analysis - Transferrin Saturation (TSAT)** |  |  |  |  |  |
| CRPa | 0.139 | 0.022 | 0.285 | <0.0001 | 21.8 |
| Hepcidinb | −0.093 | 0.024 | −0.253 | <0.0001 | 21.8 |
| Ferritin | −0.008 | 0.002 | −0.187 | <0.0001 | 21.8 |
| Age of mother | −0.68 | 0.285 | −0.161 | <0.0001 | 21.8 |

All regressions were adjusted for 4 grades of visually assessed haemolysis. Ranked according to their standardised coefficients calculated in STATA.

Funding

The research was undertaken with a research grant provided by the Bill & Melinda Gates Foundation (OPP115253). The funding agency had no role in the design and conduct of the study, and did not have any in the collection, management, analyses or interpretation of the data nor in the preparation, review, or approval of the manuscript. The Nutrition Theme of the MRC Unit The Gambia at LSHTM are supported by core funding MC-A760-5QX00 to the MRC Unit The Gambia/MRC International Nutrition Group by the UK MRC and the UK Department for the International Development (DFID) under the MRC/DFID Concordat agreement.

Availability of Data and Materials

All data will be made available to researchers upon reasonable request to the study PI and clearance by the MRCG Scientific Coordinating and Ethics Committees.

Authors’ Contributions

JHC is PhD student with MRCG at LSHTM. He contributed to the development of the protocols, study management, field data collection, development of the data analysis plan, conducting the data analysis and drafting of the manuscript.

OJ is a research clinician with MRCG at LSHTM. He contributed to the development of the protocols, study management, field data collection and patient care.

NIM is a statistician at MRCG at LSHTM. He wrote the data analysis plan in consultation with JC, CC and AMP.

SRG was a visiting B.Sc. student from Cardiff University. He contributed to the laboratory analyses and field data collection.

BJBT is a laboratory technician with MRCG at LSHTM. He contributed to the laboratory analyses and field data collection.

AMP is a Professor of International Nutrition at LSHTM and Nutrition Theme Leader at MRCG at LSHTM. He conceived the study, obtained the funding, contributed to the development of the protocols, the data analysis plan, conducting the data analysis and the drafting of the manuscript.

CC is Senior Investigator Scientist at MRCG at LSHTM and Group Leader for Iron, Infection and Anaemia. She was the PI on the trial, conceived the study, and obtained the funding. She was responsible for the overall development of the protocols, the data analysis plan, conducting the data analysis and the drafting of the manuscript.

All authors reviewed the final manuscript prior to submission.

Consent for Publication

Not applicable.

Ethics Approval and Consent to Participate

This study has been approved by The Gambia Government/MRC Joint Ethics Committee (no. SCC1525) and London School of Hygiene and Tropical Medicine Ethics Committee (ref no. 14316). The study was conducted according to Good Clinical Practice (GCP) standards. The study procedures were be explained to the neonate’s mother/guardian orally and in writing. A neonate was only recruited into the study after the written, informed consent was provided by the mother/guardian.

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.ebiom.2019.102613.
Fig. 5. Comparisons of serum iron (A = cord, B = venous), TSAT (C = cord, D = venous) and hepcidin (E = cord, F = venous) in cord and postnatal venous blood. Means ± 95% CI. FTB/NBW are BLUE columns. PTB/LBW are RED columns. PTB are DARK GREY columns. LBW are LIGHT GREY columns. Significance lines represent the comparison of PTB/LBW, PTB or LBW groups to the FTB/NBW group. ** = P < 0.01, * = P < 0.05. No significance line = P > 0.05.
All regressions were adjusted for 4 grades of visually assessed haemolysis. Ranked linear regression of factors associated with postnatal serum hepcidin.

References

[1] GBD 2016 Causes of Death Collaborators, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet 2017;390:1151–210.

[2] Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antimicrobial resistance—the need for global solutions. Lancet Infect Dis 2013;13:1057–98.

[3] Moore RE, Townsend SD. Temporal development of the infant gut microbiome. Open Biol 2019;9:190128.

[4] Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci 2010;107:11971–5.

[5] Ferretti P, Pasolli E, Tett A, Huttenhower C, Correspondence NS. Mother-to-Infant microbial transmission from different body sites shapes the developing infant gut microbiome. Cell Host Microbe 2018;24:133–45.

[6] Dominguez-Bello MG, Godoy-Vitirrio F, Knight R, Blaser MJ. Role of the microbiome in human development. Gut 2019;68:1108–14.

[7] Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antimicrobial resistance—the need for global solutions. Lancet Infect Dis 2013;13:1057–98.

[8] Moore RE, Townsend SD. Temporal development of the infant gut microbiome. Open Biol 2019;9:190128.

[9] Schable UE, Kaufmann SHE. Iron and microbial infection. Nat Rev Microbiol 2004;2:946–53.

[10] Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is upregulated during iron overload. J Biol Chem 2001;276:7811–9.

Table 4

| Predictor       | Coefficient | Standard error | Standardised coefficient | P value | R² (%) |
|-----------------|-------------|----------------|--------------------------|---------|--------|
| Univariate analysis - Serum hepcidin |             |                |                          |         |        |
| Ferritin        | 0.039       | 0.0005         | 0.354                    | 0.0001  | 14     |
| Time of bleed   | 0.0007      | 0.0001         | 0.321                    | 0.0001  | 12     |
| Transferrin     | 0.706       | 0.104          | 0.318                    | 0.0001  | 11.5   |
| Serum iron      | 0.047       | 0.089          | 0.267                    | 0.0001  | 8.2    |
| sTfR            | 0.36        | 0.092          | 0.189                    | 0.001   | 5      |
| Multivariate analysis - Serum hepcidin |             |                |                          |         |        |
| Time of bleed   | 0.0008      | 0.0009         | 0.354                    | 0.0001  | 36.1   |
| Ferritin        | 0.035       | 0.004          | 0.319                    | 0.0001  |        |
| Serum iron      | 0.413       | 0.078          | 0.232                    | 0.0001  |        |
| sTfR            | 0.286       | 0.086          | 0.15                     | 0.001   |        |
| Transferrin     | 0.218       | 0.111          | 0.01                     | 0.05    |        |

All regressions were adjusted for 4 grades of visually assessed haemolysis. Ranked according to their standardised regression coefficients calculated in STATA.

a sqrt(Ferritin), b log10 (serum iron), c sqrt(sTfR).

[11] Pietrangeli A, Hereditary hemochromatosis. Biochim Biophys Acta – Mol Cell Res 2006;1763:700–10.

[12] Barry DM, Reeve AW. Increased incidence of gram negative neonatal sepsis with intramuscular iron administration. Pediatrics 1977;60:908–12.

[13] Lorenz L, Peter A, Poets CF, Franz AR. A review of cord blood concentrations of iron status parameters to define reference ranges for preterm infants. Neonatology 2013;104:194–202.

[14] Prentice S, Jallow AT, Sinjanka J, Jallow MW, Sise EA, Kessler N, et al. Hepcidin mediates hypoferremia and reduces the growth potential of bacteria in the immediate post-natal period in human neonates. Sci Rep 2019;9(1):16596. doi: 10.1038/s41598-019-25908-w.

[15] Cross JH, Jarjou O, Mohammad NI, Prentice AM, Cerami C. Neonatal iron distribution and infection susceptibility in full term, preterm and low birthweight babies in urban Gambia: study protocol for an observational study. Gates Open Res 2019;3:1469.

[16] Ballard RL, Khoury JC, Wedig K, Wang L, Elers-Walsman B, Ripp L. New Ballard Score, expanded to include extremely premature infants. J Pediatr 1991;119:417–23.

[17] WHO. Delayed umbilical cord clamping for improved maternal and infant health and nutrition outcomes. WHO 2019 Nov 05 Available at: https://www.who.int/nutrition/publications/guidelines/cord_clamping/en/.

[18] Dugan L, Leech L, Speroni KG, Corrigher J. Factors affecting hemolysis rates in blood samples drawn from newly placed IV sites in the emergency department. J Emerg Nurs 2005;31:338–45.

[19] Szabo M, Vasarhegyi B, Balla G, Szabo T, Machy T, Tulassay T, et al. Acute postnatal increase of extracellular antioxidant defence of neonates: the role of iron metabolism. Acta Paediatr 2001;90:1167–70.

[20] Balogh A, Szabo M, Kelen D, Bokodi G, Brech J, Böshe S, et al. Prohepcidin levels during human perinatal adaptation. Pediatr Hematol Oncol 2007;24:361–8.

[21] Schrag SJ, Farley MM, Petit S, Reingold A, Weston J, Pondo T, et al. Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. Pediatrics 2016;138:e20162013.

[22] Skaar EP. The battle for iron between bacterial pathogens and their vertebrate hosts. PLoS Pathog 2010;6:e1000949.

[23] Enculescu M, Metzendorf C, Sparla R, Hahnel M, Bode J, Muckenthaler MU, et al. Modelling systemic iron regulation during dietary iron overload and acute inflammation: role of hepcidin-independent mechanisms. PLoS Comput Biol 2017;13:e1005352. https://doi.org/10.1371/journal.pcbi.1005352.

[24] Michels K, Nemeth E, Ganz T, Mehrad B. Hepcidin and host defense against infectious diseases. PLoS Pathog. 2015;11:e1004958. https://doi.org/10.1371/journal.ppat.1004958.

[25] Ganz T. Systemic iron homeostasis. Physiol Rev 2013;93:1721–41.

[26] Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090–3.

[27] Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005;106:2196–9.

[28] Protagonist Therapeutics. Protagonist therapeutics announces final phase 1 study results with novel hepcidin mimetic. PTG-300 2019 Nov 05 Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-final-phase-1-study-results-with-novel-hepcidin-mimetic-ptg-300-300571268.html.

[29] Cross JH, Bradbury RS, Fulford AJ, Jallow AT, Wegmuller R, Prentice AM, et al. Oral iron acutely elevates bacterial growth in human serum. Sci Rep 2015;5:16670.

[30] Vifor Pharma. Vifor pharmaceutical inhibitors enter phase-I clinical trial. 2019. Available at: http://www.viforpharma.com/en/media/press-releases/201802/2167159